As medical understanding of the genotype/phenotype correlation of a disease becomes clearer, genetic testing can be expected to become a mainstay in the clinical setting. While the application of genetic testing to the clinical setting is very much in line with the larger medical goals of preventative and personalized medicine, there are many unanswered questions with regard to genetic testing. Speakers: Dr. Mansoor Mohammed, Genomics Portraits Inc., Dr. Brian Underdown, Managing Director, MDS Capital, Dr. June Carroll, Sydney G. Frankfort Chair in Family Medicine Mt.Sinai Hospital, Dr. Peter N. Ray, Head, Molecular Genetics Department of Paediatric Laboratory Medicine. HSC Professor, Molecular and Medical Genetics, University of Toronto

1. US Genetics Diagnostics Markets March 2006 2006 MaRS Emerging Technologies Briefings Extracted from Frost and Sullivan Market Engineering, October 2005 SUPPLEMENTAL INDUSTRY RESEARCH

6. Top industry Challenges for US genetic markers market from 2005-2011 Extracted from Frost and Sullivan Market Engineering, October 2005 Low Medium Medium Hospital Laboratories are reluctant to adopt new molecular procedures Low Medium Medium Divers population mandates the need for ethnically comprehensive genetic panels Low Medium Medium Large volumes of testing by home-brew techniques continue to limit the sales of kits Low Medium Medium Obtaining FDA approval for pharmacogenomic testing poses significant challenges for companies Medium Medium Medium Absence of precedent restrains pharmaceutical industry to use pharmacogenomics tests for drug development Low Medium High Healthcare conservatism impedes testing uptake High High High Lack of Healthcare providers education hinders test uptake 5-7 years 3-4 years 1-2 years Challenge

16. Addenum from OGI Ontario Companies in Genetic Diagnostic field Thanks to Rhonda Tannenbaum of the Ontario Genomics Institute (OGI) for information Health Gene offers an extensive menu of state-of-the-art molecular diagnostic tests. HealthGene Epocal biochips combine features lab-on-a-chip microfluidics and microarrays (DNA arrays, protein arrays, cell arrays) into a single technology. Epocal Tm Bioscience is developing Genetic testing on a multi-plex platform for genetic mutations related to hematology, toxicology, and other debilitating genetic disorders. Companies CF test is the first such test to receive FDA approval and their technology has been adopted by leading reference laboratory such as Mayo Clinic and Specialty Labs. TM Biosciences GDI’s Genexus Analyzer platform and Triplex Assay are new platform technology for conducting DNA diagnostic tests. GDI's platform has an unprecedented ability to effectively and efficiently detect Single Nucleotide Polymorphisms (SNP's). Genetic Diagnostics Inc. Genesis Genomics implements mitochondrial DNA (mtDNA) sequencing technology and bioinformatics to exploit specific mtDNA data for commercial applications in medical diagnostics. Genesis Genomics Chondrogene uses functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The applications of this technology is in the discovery and development of diagnostic and therapeutic products across 4 disease areas: Cancer, Central Nervous System Disorders, Cardiovascular Disease and Arthritis. Chondrogene Gene Focus has developed state-of-the-art readers for genetic and tissue arrays and biochips based on patented confocal laser imaging technology as well as imaging system for non-standard microarrays and liquid biochips. Biomedical Photometrics Inc. & GeneFocus Description Company Name

17. Addenum from OGI OGI award recipient in Genetic Diagnostic Thanks to Rhonda Tannenbaum of the Ontario Genomics Institute (OGI) for information OGI Competition III Award – Quantum Dot Diagnostics: simultaneous genomic and proteomic profiling of multiple pathogens at point-of-care Dr. Kevin Kain OGI Competition II Award - Nucleic acid diagnostic systems Drs. Ulli Krull/Alex MacKenzie/Paul Piunno OGI Applied Health Award – Development and Application of Functional Genomics Technologies Dr.John Dick OGI Applied Health Award – Protein expression profiling platform for Heart Disease Biomarker Discovery Dr.s Peter Liu/Andrew Emilli OGI Applied Health Award – assessment for risk of colorectal tumours in Canada Dr. Brent Zanke Description Researcher